# Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia

> **NCT00354809** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 68 (actual)

## Conditions studied

- Sleep Initiation and Maintenance Disorders
- Insomnia

## Interventions

- **DRUG:** GW679769

## Key facts

- **NCT ID:** NCT00354809
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2015-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354809, "Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00354809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*